| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18802151 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 105 journal articles in the PubMed database | Email to a friend | | |
| Geoerger B, Doz F, Gentet JC, et al.
Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. [Clinical Trial, Phase I, Journal Article, Multicenter Study]
J Clin Oncol 2008 Sep 20; 26(27):4394-400.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Mani S, Vogelzang NJ, Bertucci D, et al.
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. [Clinical Trial, Clinical Trial, Phase I, Journal Article]
Cancer 2001 Sep 15; 92(6):1567-76.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Scheithauer W, Kornek GV, Raderer M, et al.
Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. [Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article]
Ann Oncol 2002 Oct; 13(10):1583-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Sebag-Montefiore D, Glynne-Jones R, Falk S, et al.
A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study. [Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article]
Br J Cancer 2005 Oct 31; 93(9):993-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Faivre S, Le Chevalier T, Monnerat C, et al.
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. [Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article]
Ann Oncol 2002 Sep; 13(9):1479-89.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Fox E, Maris JM, Widemann BC, et al.
A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors. [JOURNAL ARTICLE]
Clin Cancer Res 2006 Aug 15; 12(16):4882-4887.
Abstract | Full Citation | Find Related Articles | | Fox E, Maris JM, Widemann BC, et al.
A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors. [JOURNAL ARTICLE]
Clin Cancer Res 2008 Feb 15; 14(4):1111-1115.
Abstract | Full Citation | Find Related Articles | | Wasserman E, Cuvier C, Lokiec F, et al.
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. [Clinical Trial, Clinical Trial, Phase I, Journal Article, Multicenter Study]
J Clin Oncol 1999 Jun; 17(6):1751-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Comella P, Casaretti R, De Rosa V, et al.
Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. [Clinical Trial, Clinical Trial, Phase I, Journal Article]
Ann Oncol 2002 Dec; 13(12):1874-81.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
